Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Avonex

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Interferon beta-1a treatment reduced the rate at which high-risk individuals develop clinically definite multiple sclerosis by 44% compared to placebo, according to a study published in the Sept. 28 New England Journal of Medicine. The 383-patient study also showed that 20 mcg Avonex injected intramuscularly once a week for up to three years had "a highly significant positive impact in reducing the rate at which patients developed brain abnormalities, or lesions, visible on MRI scans" compared to placebo, according to the company. Biogen plans to apply for an expanded label to reflect this early treatment regime

You may also be interested in...

Why Value-Based Health Care Is Here To Stay

COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.

VC View: Deal-Making During A Pandemic And 2021 Expectations

In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.

HHS Secretary’s Regs Sign-Off Requirement Will Kick FDA’s Draft QSR Into 2021, Expert Predicts

Kim Trautman, who authored the US FDA’s Quality System Regulation in the 1990s, tells Medtech Insight that the agency probably won’t release a draft of its updated, harmonized QSR until next year thanks in part to a recent move by HHS secretary Alex Azar to personally sign off on every rule.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts